Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KYMR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsKymera appoints Terence Rooney as CMO; Jared Gollob retires after 8 years
Filed July 27, 2026 · Period ending July 27, 2026 · ~1 min read
Key Changes
-
high
Terence Rooney, MD, appointed Chief Medical Officer effective July 27, 2026, bringing extensive immunology drug development experience from J&J, Eli Lilly, and Roche, including work on approved medicines OLUMIANT, STELARA, and TREMFYA.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Jared Gollob, MD, retiring as CMO for personal reasons after eight years; will remain as advisor through December 31, 2026. Departure not due to any disagreement with company practices or policies.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Dr. Rooney will lead Kymera's global clinical development strategy and advancement of its oral immunology portfolio across multiple immuno-inflammatory diseases.
Exhibit 99.1 view on EDGAR →
Summary
Kymera Therapeutics announced a planned leadership transition in its medical organization. Terence Rooney, MD, has been appointed Chief Medical Officer effective July 27, 2026, succeeding Jared Gollob, MD, who is retiring after eight years with the company. Dr.
Gollob's departure is for personal reasons and explicitly not the result of any disagreement with company practices or policies; he will remain as an advisor through year-end to support continuity. Dr. Rooney brings substantial immunology drug development credentials, most recently serving as Senior Vice President at Johnson & Johnson leading immunology portfolio strategy and global compound development teams.
His career spans senior R&D roles at Eli Lilly and Roche, and he contributed to successful marketing applications for multiple approved immunology medicines including OLUMIANT, STELARA, and TREMFYA. His experience across small molecules, biologics, and cell therapies aligns with Kymera's oral degrader platform. For a clinical-stage company advancing an immunology portfolio, the incoming CMO's track record taking therapies from early development through commercialization represents relevant expertise for the next phase of pipeline advancement.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Jared Gollob, M.D., communicated his intention to retire from his role as Chief Medical Officer (“CMO”) of Kymera Therapeutics, Inc. (the “Company”) and submitted his resignation on July 27, 2026. Dr. Gollob will continue providing services to the Company as an advisor until December 31, 2026. Dr. Gollob informed the Company that he resigned as CMO for personal reasons, and not as the result of any disagreement with the Company’s practices or policies.
Effective July 27, 2026, Terence Rooney, M.D., will succeed Dr. Gollob as CMO of the Company.
Chief Medical Officer Jared Gollob is retiring for personal reasons and will transition to an advisory role through year-end. Terence Rooney has been appointed as the new CMO effective immediately. The filing explicitly states the departure is not due to any disagreement with company practices or policies.
Event · Item 7.01 — Regulation FD Disclosure
Kymera appoints Dr. Rooney as CMO; Dr. Gollob retires.
Added in current filing · verify on EDGAR →
On July 27, 2026, the Company issued a press release announcing the appointment of Dr. Rooney as CMO and the retirement of Dr. Gollob.
Kymera announced a leadership transition in its medical organization. Dr. Rooney has been appointed Chief Medical Officer, while Dr. Gollob is retiring from the company. The 8-K does not provide additional details about the timing, transition plan, or backgrounds of the individuals involved.
Event · Exhibit 99.1
Kymera appoints Terence Rooney, MD, as Chief Medical Officer; Jared Gollob, MD, to retire after eight years.
Added in current filing · view on EDGAR →
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Terence Rooney, MD, as Chief Medical Officer. Dr. Rooney is an accomplished drug development leader with extensive experience advancing immunology therapies across the full development lifecycle, from early clinical stages through commercialization and franchise expansion, helping bring important new medicines to patients around the world. In his role, Dr. Rooney will lead Kymera’s global clinical development strategy and guide the advancement of the Company’s oral immunology portfolio across multiple immuno-inflammatory diseases.
Kymera appointed Terence Rooney, MD, as Chief Medical Officer. Dr. Rooney brings extensive immunology drug development experience spanning early clinical stages through commercialization. He will lead the company's global clinical development strategy and advance its oral immunology portfolio across multiple immuno-inflammatory diseases.
Added in current filing · view on EDGAR →
He succeeds Jared Gollob, MD, who will retire from his role after eight years with the Company and will remain as an advisor through the end of the year.
Jared Gollob, MD, is retiring from his Chief Medical Officer role after eight years with Kymera. He will remain as an advisor through the end of 2026, providing continuity during the leadership transition.
Added in current filing · view on EDGAR →
Prior to joining Kymera, Dr. Rooney served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson, where he led global compound development teams and portfolio strategy and operations across immunology. Earlier in his career, he held senior leadership roles across immunology R&D at Eli Lilly and Roche, including work at the interface of discovery, translational medicine and clinical development. Across his career, his work has spanned small molecules, peptides, biologics and cell therapies, combination and precision therapy strategies, and therapeutic areas including dermatology, respiratory, rheumatology, gastroenterology and rare diseases. Dr. Rooney has contributed to successful marketing applications for groundbreaking medicines including ICOTYDE®, IMAAVY®, OLUMIANT®, STELARA®, and TREMFYA®.
Dr. Rooney most recently served as Senior Vice President at Johnson & Johnson leading immunology portfolio strategy and global compound development teams. His career includes senior immunology R&D roles at Eli Lilly and Roche, and he contributed to successful marketing applications for multiple approved medicines including OLUMIANT, STELARA, and TREMFYA. His experience spans small molecules, biologics, cell therapies, and multiple therapeutic areas within immunology.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 28, 2026 · How we verify